Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Interventional × Small Cell Lung Cancer Recurrent × Clear all

Phase

Status

Sponsor Class

OTHER 2 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 166 Neoplasms 92 Colorectal Neoplasms 77 Stomach Neoplasms 73 Uterine Cervical Neoplasms 60 Carcinoma, Non-Small-Cell Lung 60 Carcinoma, Hepatocellular 49 Prostatic Neoplasms 42 Lung Neoplasms 41 Rectal Neoplasms 38 Esophageal Neoplasms 33 Pancreatic Neoplasms 32 Ovarian Neoplasms 31 Colonic Neoplasms 29 Motor Activity 28 Head and Neck Neoplasms 28 Recurrence 26 Neoplasm Metastasis 26 Lymphoma 23 Small Cell Lung Carcinoma 22 Lymphoma, Non-Hodgkin 22 Multiple Myeloma 21 Polycystic Ovary Syndrome 20 Melanoma 20 Leukemia, Myeloid, Acute 18 Precursor Cell Lymphoblastic Leukemia-Lymphoma 17 Pain 17 Nasopharyngeal Carcinoma 16 Fallopian Tube Neoplasms 16 Brain Neoplasms 16

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03262454 2022-04-06

Atezolizumab

National Cancer Center, Korea

Phase 2 Unknown

Small Cell Lung Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡